

**ASX ANNOUNCEMENT**

**ASX CODE: HHI**

**8 November 2021**

## Health House launches Germany-wide study on effect of cannabis extracts

### Highlights

- Health House International's 100% owned German subsidiary, CanPharma, starts non-interventional study examining effect of cannabis extracts on quality of life and their safety and tolerability.
- The study - targeting 600 patients - uses CanPharma extracts and aims to improve the clinical evidence for the use and effectiveness of cannabis-based medicines
- Increased evidence in this area will drive confidence and understanding of doctors and increase prescription of medicinal cannabis
- The study has been launched by CanPharma (Germany) and conducted by Kalapa Clinic (Germany/Spain)

**Health House International Ltd (ASX:HHI) (Health House or the Company** or together with the entities it controls **the Group**), an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe, is pleased to announce the launch of a non-interventional observational study in Germany considering the effect on quality of life of patients and the safety and tolerability of cannabis medication.

The study has been launched by CanPharma (Germany) and supported by Kalapa Clinic (Germany/Spain), both 100% owned by Health House; with a focus on cannabis extracts and improving understanding and confidence of medical professionals in prescribing which are core parts of the Company's growth strategy in the German market.

**David Attwood, CEO of Health House** said *"Due to the limited historical data on the medical use of cannabis, there is often uncertainty when it comes to prescribing. Optimal patient care needs medical progress as well as professional education. In cooperation with leading experts, CanPharma is working to advance the clinical evidence for the use and effectiveness of cannabis-based medicines."*

*"Cannabis treatment must be tailored to the individual needs of patients," says **Dr Henrik Sprengel, Executive Director of Health House and CEO of CanPharma.** "Gaining knowledge about the safety and tolerability of our cannabis extracts under everyday conditions is an important task that will drive confidence of medical professionals in prescribing. We are pleased and proud to be doing pioneering work here and to be driving the acquisition of scientific data."*

The open, prospective, non-interventional study using CanPharma's own-brand full spectrum cannabis extracts starts now and will run for a period of two years, with the first interim results expected in around 6 months. The analysis of data sets from up to 600 patients to be collected in the non-interventional study will support treatment safety as well as the ongoing improvement and standardisation of individualised cannabinoid therapy. The individual observation period for each participant is six months. CanPharma's observational study will be conducted at various centres in Germany.

The observational study is being conducted by Kalapa Clinic, an independent part of the Health House group, whose medical experts have years of experience and in-depth expertise in cannabis therapy. Kalapa was the first medical cannabis counselling centre to be established in Europe. It advises health professionals and patients on the appropriate use of cannabis-based medicines for the treatment of various indications.

This announcement has been approved and authorised for release by the board of Health House International Limited.

**David Attwood**  
**Chief Executive Officer**

### **About Health House**

The Health House International Group is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.

The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

**For more information, please visit [www.healthhouse.com.au](http://www.healthhouse.com.au)**

**Address**

Level 3  
101 St Georges Tce  
Perth WA 6000  
AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [admin@healthhouse.com.au](mailto:admin@healthhouse.com.au)  
W: [www.healthhouse.com.au](http://www.healthhouse.com.au)

ACN 149 197 651

**Contact**

**David Attwood**  
Chief Executive Officer  
[David.attwood@healthhouse.com.au](mailto:David.attwood@healthhouse.com.au)

**Tim Slate**

Company Secretary  
[tim.slate@healthhouse.com.au](mailto:tim.slate@healthhouse.com.au)